Generic pipeline of products is yet again a smart strategy.
Allows revenue regardless of how large to trickle in providing effective cash flow that can be used to streamline patented products they are wanting to get through the FDA process.
This is one major win for the 3 year plan with this equity.
Very very interesting to see where this stock ends up in the next 12-24 months
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.747M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 617000 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 646239 | 2 |
View Market Depth
| Last trade - 09.06am 19/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |
Day chart unavailable